Sakaguchi et al. demonstrated that NPM1-mutant AML with a low FLT3-ITD allelic ratio is not associated with favorable outcomes, and survival of patients with this mutation is improved by allogeneic HCT26. This evidence concerns the gene FLT3 and acute myeloid leukemia.